Wall Street analysis firm First Albany has initiated coverage of Trimeris but did so with a “neutral” rating. First Albany announced coverage on Tuesday.

The firm said limited production and pricing could affect Trimeris’ new HIV drug Fuzeon, according to Reuters.

Trimeris (Nasdaq: TRMS) stock surged 3.5 percent on Wednesday to $52.46.

Trimeris: www.trimeris.com